- ￥1100 - 7680
- MedChemExpress(MCE)
- 美国
- HY-15319
- 2025年07月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
473719-41-4
- 规格：
10 mM * 1 mL/2 mg/5 mg/10 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥1912.0 |
|---|---|---|---|
| 规格： | 2 mg | 产品价格： | ￥1100.0 |
| 规格： | 5 mg | 产品价格： | ￥1440.0 |
| 规格： | 10 mg | 产品价格： | ￥2040.0 |
| 规格： | 50 mg | 产品价格： | ￥7680.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
AMG 487
CAS No. : 473719-41-4
MCE 国际站：AMG 487
产品活性：AMG 487 是一种有效的、具有口服活性的、选择性的趋化因子受体3 (CXCR3) 拮抗剂，抑制 CXCL10和 CXCL11与 CXCR3 结合的 IC50 值分别为 8.0 和 8.2 nM。
研究领域：GPCR/G Protein | Immunology/Inflammation
作用靶点：CXCR
In Vitro: AMG 487 inhibits CXCR3-mediated cell migration by the three CXCR3 chemokines (IP-10 IC50=8 nM, ITAC IC50=15 nM, and MIG IC50=36 nM). Furthermore, AMG 487 inhibits calcium mobilization in response to ITAC (IC50=5 nM).
AMG487 (1 μM) develops into fewer lung metastases, and the lungs are significantly smaller than vehicle-treated lungs.
AMG487 abrogates proliferation/survival of C26 tumour cells.
In Vivo: AMG 487 (0.03-10 mg/kg, s.c.) exhibits significant reduction in cellular infiltration into the lungs in a dose dependent manner.
AMG487 (5 mg/kg, s.c., twice daily) develops fewer metastases than that in vehicle-treated mice.
AMG487 (5 mg/kg, s.c.)-treated mice exhibits fewer pulmonary nodules than the control mice in both the models. AMG487 reduces the tumour volume.
相关产品：Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Immunology/Inflammation Compound Library | Anti-Cancer Compound Library | Small Molecule Immuno-Oncology Compound Library | Endocrinology Compound Library | Orally Active Compound Library | Chemokine Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Plerixafor | SB225002 | Kynurenic acid | Reparixin | AZD8797 | Navarixin | AZD-5069 | Motixafortide | SCH 546738 | TAK-779 | SX-682 | Decursin | Baohuoside I | NUCC-390 dihydrochloride | Mavorixafor trihydrochloride | NBI-74330 | Ladarixin | ML 145 | ML339 | ACT-1004-1239 | SB-265610 | VUF11207 fumarate | CXCR7 antagonist-1 | IT1t dihydrochloride | Danirixin | LY2510924 | PS372424 hydrochloride | TC14012
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Silver Acetate Autometallography (AMG)
In the early eighties, a series of papers were published by Gorm DANSCHER, Aarhus, Denmark, to introduce a reliable and easy-to-handle technique for light microscopical and ultrastructural autometallographic (AMG) studies. Specific methods
分子病理，选择分子靶向治疗。 RARP抑制剂成为卵巢癌个性化治疗的新宠。DNA修复PARP抑制剂奥拉帕尼作为靶向药物出现在2013年卵巢癌NCCN指南中。虽然FDA并未批准其用于卵巢癌的治疗，但PARP与BRCA1/2基因在DNA修复过程中的关系，使得PARP抑制剂成为卵巢癌个性化治疗的新宠。2012年发表在新英格兰杂志上的一篇报道，153位卵巢癌患者经过奥拉帕尼与安慰剂治疗比较，结果显示奥拉帕尼具有抗肿瘤活性，结果具有统计学意义。 抗血管类药物新成员AMG386。日前，欧盟已经批准
Flow Cytometric Determination of Micronucleus Frequency
in our understanding of key toxicological issues related to genotoxins and their effects at the cellular and organism levels. Recently, the final acceptance of the in vitro MN test guideline 487 (OECD Guideline for Testing of Chemicals, In vitro mammalian cell
技术资料暂无技术资料 索取技术资料
